NerveAide

Cover Block

Company	NerveAide
Tagline	Wearable neuro-rehab solutions combining FES/NMES, smart sensors, and app guidance for mobility and independence. [NerveAide]
Headquarters	Toronto, Canada
Founded	2017 [F6S]
Stage	Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+) [NerveAide]
Funding Label	Seed

Links

• Website: https://nerveaide.com/
• LinkedIn: https://fr.linkedin.com/company/nerveaide

Executive Summary

NerveAide is a Toronto-based neurotechnology company building a suite of clinician-guided wearable devices aimed at restoring mobility for patients with central nervous system disorders [NerveAide, retrieved 2024]. The company, founded in 2017, has developed a modular product line that combines functional electrical stimulation (FES/NMES), smart sensors, and a companion app, positioning its hardware-plus-software model to address rehabilitation from clinic to home [NerveAide, retrieved 2024]. Its founding team includes Pouria Mireshghi as CEO, with co-founder Elham Mireshghi bringing an anthropological perspective [LinkedIn, retrieved 2024] [LinkedIn, retrieved 2026].

NerveAide has participated in prominent Canadian accelerators, including Creative Destruction Lab and MaRS, and closed a Seed round in October 2022 [Tracxn, 2025]. The primary challenge for investors over the next 12-18 months will be validating commercial traction and clinical adoption, as public information currently consists largely of company-authored materials without third-party validation of customer deployments or partnership announcements [NerveAide, retrieved 2024].

Data Accuracy: YELLOW -- Core product and company description are confirmed via primary website. Founder identities are partially corroborated via LinkedIn. Seed round date is confirmed via a single aggregator; amount and lead are not public.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Seed

How the Company Got Here

NerveAide was founded in 2017 in Toronto, Canada, positioning itself at the intersection of neurotechnology and rehabilitation hardware [F6S, retrieved 2024]. The company's public narrative centers on a mission to restore movement and rebuild lives by making clinician-guided neurotechnology accessible, moving from clinical settings into the home [NerveAide Mission & Impact, retrieved 2024]. The company describes itself as being established by a group of entrepreneurs, engineers, and neurologists [NerveAide, retrieved 2024].

Key operational milestones are primarily evidenced by the company's participation in prominent Canadian accelerators. NerveAide is an alumnus of both the Creative Destruction Lab (CDL) and MaRS accelerator programs [Tracxn, retrieved 2026]. The company closed a Seed funding round in October 2022 [Tracxn, retrieved 2026]. Since its founding, NerveAide has developed and publicly launched a portfolio of at least six distinct wearable medical devices targeting conditions from foot drop to sleep apnea [NerveAide, retrieved 2024].

Data Accuracy: YELLOW -- Founding year and accelerator participation are corroborated; founding team details and funding specifics rely on a single source.

Product and Technology

NerveAide’s product suite is built on a consistent technical foundation, targeting a specific clinical workflow. The company designs wearable neuro-rehabilitation devices that combine functional electrical stimulation (FES/NMES), integrated smart sensors, and a companion mobile application for guidance [NerveAide, retrieved 2024]. This approach aims to translate a clinician-prescribed therapy from a clinical setting into a user-managed routine at home.

The portfolio is segmented by anatomical application and condition, suggesting a modular strategy for patient pathways. Key products include:

• NeStim. A dual-channel device providing both neuromuscular electrical stimulation (NMES) and transcutaneous electrical nerve stimulation (TENS), with app guidance, USB-C charging, and Bluetooth® 5 connectivity [NerveAide, retrieved 2024].
• NEwalk+. A system designed for individuals with foot drop and thigh weakness [NerveAide, retrieved 2024].
• NeArm & NeGrasp. Targeted solutions for upper-limb rehabilitation, supporting reach, elbow control, and hand function [NerveAide, retrieved 2024].
• NeBack & NeBow. Devices focused on postural support for the trunk and leg muscle strengthening for bow-leg alignment, respectively [NerveAide, retrieved 2024].
• neSNORE®. A device indicated for snoring and mild sleep apnea relief [Seniors by NerveAide, retrieved 2026].

The technology stack appears to integrate low-energy wireless connectivity, sensor data processing, and a software layer for parameter personalization and progress tracking [NerveAide, retrieved 2024]. The company states its products are clinician-guided and emphasizes quality and regulatory standards [NerveAide].

Data Accuracy: YELLOW -- Product details are confirmed from the company's own website, but technical specifications and regulatory status lack independent verification.

Where the Demand Sits

The market for neuro-rehabilitation technology is being reshaped by a convergence of demographic pressures, clinical evidence, and a policy-driven shift toward cost-effective home care. NerveAide operates at the intersection of several large and growing healthcare segments.

The company's addressable market can be approximated by examining the prevalence of the neurological conditions it targets. Stroke is a leading cause of serious long-term disability in the United States, with an estimated annual incidence of nearly 800,000 cases [CDC]. Multiple sclerosis affects close to 1 million people in the U.S. alone [National MS Society]. The global market for physical rehabilitation equipment was valued at approximately $15 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 6% through 2030 [Grand View Research, 2023].

Key demand drivers extend beyond patient demographics. There is a well-documented shortage of physical therapists and rehabilitation specialists, creating pressure to extend clinical resources through technology [American Physical Therapy Association]. Concurrently, payers are increasingly incentivizing home-based care and value-based outcomes, which favors durable medical equipment designed for patient self-management. The clinical evidence base for neurostimulation in motor recovery continues to expand [Journal of NeuroEngineering and Rehabilitation].

Metric	Value
Global Rehab Equipment Market 2022	15 $B
Projected CAGR 2023-2030	6 %
U.S. Stroke Incidence (annual)	0.8 million patients
U.S. MS Prevalence	1 million patients

Data Accuracy: YELLOW -- Market sizing is drawn from analogous third-party reports and public health data; company-specific SAM/SOM is not publicly available.

Competitive Landscape

NerveAide operates in a crowded and fragmented market for neuro-rehabilitation technology. The competitive map can be broken into three primary segments. First, incumbent medical device giants like Ottobock and Bioness dominate the prescription-grade, insurance-reimbursed market for foot drop and upper-limb rehabilitation. Second, a wave of challenger startups focusing on digital therapeutics and at-home recovery, such as Hinge Health and Kaia Health, are expanding their scope into adjacent neurological conditions. Third, adjacent substitutes include traditional physical therapy services, over-the-counter TENS units for pain management, and consumer wellness wearables.

NerveAide’s defensible edge today appears to be its product breadth and modularity. Its portfolio spans foot drop (neWALK+), upper limb (NeArm), leg strengthening (NeLeg), posture (NeBack), and sleep support (neSNORE) [NerveAide]. This approach of a “modular pathway” allows for cross-selling within a single patient’s evolving rehab journey. However, this edge relies on maintaining a technological and usability advantage across multiple product lines. Durability will depend on securing regulatory clearances and building a body of clinical evidence for each device.

The company is most exposed in two key areas. It lacks the reimbursement infrastructure that is critical for adoption in the core neuro-rehab patient population. Furthermore, NerveAide does not appear to own a direct clinical channel. Without public partnerships with major hospital networks or rehabilitation clinics, the route to the prescribing physician remains unclear.

Data Accuracy: YELLOW -- Competitive landscape is derived from market structure analysis; no direct competitor data is publicly disclosed.

Opportunity

If NerveAide can successfully navigate the regulatory and commercial path to becoming a standard-of-care tool in neurorehabilitation, the prize is a durable position in a multi-billion-dollar market for chronic condition management.

The headline opportunity is to become the category-defining, clinician-prescribed platform for at-home neurorehabilitation, moving beyond a collection of devices to an integrated, data-driven care pathway. The company has already articulated a modular product architecture designed for expansion, with distinct devices for foot drop, upper-limb function, posture, and sleep support [NerveAide, retrieved 2024].

Growth Scenarios

Scenario	What happens	Catalyst	Why it's plausible
Regulatory & Reimbursement Win	NeWalk+ or a similar flagship device receives a specific CPT code or favorable coverage decision.	Publication of a positive clinical outcomes study.	The product is explicitly designed for clinical use and home transition [NerveAide, retrieved 2024].
Vertical Integration with Large Health System	A major integrated delivery network (IDN) adopts the NerveAide suite as its standard post-acute neurorehab toolkit.	A successful multi-site pilot program with a named health system partner.	The company's messaging is heavily oriented toward clinician guidance and the clinic-to-home continuum [NerveAide, retrieved 2024].
Consumer-DTC Breakthrough	The NeStim device gains traction as a direct-to-consumer wellness product.	A strategic marketing partnership with a major athletic retailer or wellness influencer network.	NeStim is marketed for both clinical tone management and drug-free pain relief [NerveAide, retrieved 2024].

Data Accuracy: YELLOW -- The opportunity analysis is built on the company's stated product strategy and market positioning.

Sources

1. [NerveAide, retrieved 2024] NerveAide - Helping people regain mobility and independence. | https://nerveaide.com/
2. [NerveAide About, retrieved 2024] NerveAide About | https://nerveaide.com/en/about
3. [NerveAide Mission & Impact, retrieved 2024] NerveAide Mission & Impact | https://nerveaide.com/en/mission-impact
4. [F6S, retrieved 2024] F6S profile | https://www.f6s.com/company/nerveaide
5. [LinkedIn, retrieved 2024] Pouria Mireshghi - Co-Founder and CEO at NerveAide | https://fr.linkedin.com/in/mireshghi
6. [Tracxn, 2025] Nerve - 2025 Company Profile, Team, Funding & Competitors - Tracxn | https://tracxn.com/d/companies/nerveaide
7. [LinkedIn, retrieved 2026] Elham Mireshghi - Private Clinic | https://www.linkedin.com/in/elham-mireshghi/
8. [Seniors by NerveAide, retrieved 2026] Seniors by NerveAide | https://nerveaide.com/en/seniors
9. [CDC] Centers for Disease Control and Prevention | https://www.cdc.gov/stroke/facts.htm
10. [National MS Society] National Multiple Sclerosis Society | https://www.nationalmssociety.org/What-is-MS/MS-FAQ-s
11. [Grand View Research, 2023] Grand View Research, Physical Rehabilitation Equipment Market Report | https://www.grandviewresearch.com/industry-analysis/physical-rehabilitation-equipment-market
12. [American Physical Therapy Association] American Physical Therapy Association | https://www.apta.org/your-career/careers-in-physical-therapy/workforce-data
13. [Journal of NeuroEngineering and Rehabilitation] Journal of NeuroEngineering and Rehabilitation | https://jneuroengrehab.biomedcentral.com/